A5052104940- CAR-T cell therapy research
- Cytomegalovirus and herpesvirus research
- Immune Cell Function and Interaction
- Viral Infectious Diseases and Gene Expression in Insects
- Hematopoietic Stem Cell Transplantation
- Virus-based gene therapy research
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Polyomavirus and related diseases
- Biosimilars and Bioanalytical Methods
- Systemic Sclerosis and Related Diseases
- Herpesvirus Infections and Treatments
- Viral-associated cancers and disorders
- Systemic Lupus Erythematosus Research
- T-cell and B-cell Immunology
Cambridge University Hospitals NHS Foundation Trust
2024
Great Ormond Street Hospital
2013-2023
University College London
2010-2023
Institute of Child Health
2011
The Royal Free Hospital
2010
Abstract In the context of relapsed and refractory childhood pre-B cell acute lymphoblastic leukemia (R/R B-ALL), CD19-targeting chimeric antigen receptor (CAR)-T cells often induce durable remissions, which requires persistence CAR-T cells. this study, we systematically analyzed CD19 10 children with R/R B-ALL enrolled in CARPALL trial via high-throughput single-cell gene expression T sequencing infusion products serial blood bone marrow samples up to 5 years after infusion. We show that...
Previous studies have established that adoptive immunotherapy with donor-derived virus-specific T cells can prevent/treat viral complications post-stem cell transplant and regulatory show promise as inhibitors of graft-versus-host disease. On the basis flow cytometric analysis upregulation activation markers after stimulation peptide pools, we developed a rapid clinically applicable protocol for simultaneous selection (after pools immunodominant antigens cytomegalovirus, Epstein-Barr virus,...
Abstract Chimeric antigen receptor (CAR)-modified T-cells have become established as an effective treatment of haematological cancers. In the context relapsed and refractory childhood pre-B cell acute lymphoblastic leukaemia (B ALL), CD19 targeting CAR often induce durable remissions. One most critical determinants achieving a response is persistence T-cells. Here, we systematically analysed T cells ten children with or B ALL enrolled in CARPALL trial (NCT02443831). We performed high...
Delayed immune reconstitution is a major challenge after matched unrelated donor (MUD) stem cell transplant (SCT). In this randomized phase 2 multi-center trial, Adoptive Immunotherapy with CD25/71 allodepleted T cells to improve immunity (NCT01827579), the authors tested whether (ADTs) can safely be used alemtuzumab-based MUD SCT for hematological malignancies.